In non‐GIST STSs, the currently approved targeted therapies are limited to the multi‐target TKI pazopanib, which targets VEGFR‐1, VEGFR‐2, and VEGFR‐3, PDGFRα and PDGFR‐β; and KIT (Lee et al, 2019). Here, KIT is linked to gastrointestinal stromal tumor.